Company profile: Hexagon Bio
1.1 - Company Overview
Company description
- Provider of data-driven biotech solutions developing targeted small molecule therapeutics, including drug-target prediction via the TICker algorithm to identify microbial secondary metabolites that inhibit cancer-related proteins; DNA sequencing to build the world's largest database of microbial genomes and metabolites; compound production via the HEx platform using heterologous expression; and ADC payloads from natural products for oncology.
Products and services
- DNA Sequencing: Industrial-scale effort builds the world's largest database of microbial genomes and metabolites, delivering access to diverse, unstudied chemicals for therapeutic discovery
- Drug-Target Prediction: Custom-engineered TICker algorithm predicts microbial secondary metabolites that inhibit cancer-related proteins, guiding targeted small molecule discovery from natural product pathways
- Compound Production: Modular HEx platform produces novel compounds via heterologous expression, forcing expression of secondary metabolites to yield natural product-derived small molecules
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Hexagon Bio
C2i Genomics
HQ: United States
Website
- Description: Provider of cloud-based cancer diagnostic services for pharmaceutical and diagnostic organizations, offering the C2-Intelligence Platform that leverages whole-genome sequencing and AI to detect minimal residual disease, low-input liquid biopsy, and services for MRD-guided adjuvant treatment, organ preservation decisions, treatment response monitoring, and early recurrence detection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full C2i Genomics company profile →
LaserGen
HQ: United States
Website
- Description: Provider of biotechnology technologies for genomics and sequencing applications, developing and commercializing tools that detect heritable and somatic sequence variations in the human genome for use as diagnostic tools.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LaserGen company profile →
Strata Oncology
HQ: United States
Website
- Description: Provider of precision oncology solutions, including Strata Select, a DNA/RNA-based molecular profiling test guiding immunotherapy and other treatment selection for advanced cancer; the Immunotherapy Response Score predicting benefit of anti-PD-1/PD-L1 monotherapy; and clinical trials such as Strata PATH and Strata Trial enabling biomarker-guided evaluation and access to approved and investigational therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Strata Oncology company profile →
Syros
HQ: United States
Website
- Description: Provider of a gene control platform that systematically analyzes regulatory regions of the genome to develop small-molecule medicines that control gene expression, and developer of oral therapeutics including tamibarotene (selective RARα agonist) in clinical development for genomically defined HR-MDS and AML, and previously clinical assets SY-2101 (oral arsenic trioxide for APL) and SY-5609 (CDK7 inhibitor for pancreatic cancer).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Syros company profile →
Cygnus Technologies
HQ: United States
Website
- Description: Provider of generic kits, immunoassay reagents, and antibody and assay development services to pharmaceutical and biotechnology industries. Specializes in custom antibody and assay development for host cell protein detection in recombinant pharmaceuticals and supplies specialized analytical products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cygnus Technologies company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Hexagon Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Hexagon Bio
2.2 - Growth funds investing in similar companies to Hexagon Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Hexagon Bio
4.2 - Public trading comparable groups for Hexagon Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →